Nexstim Plc · OMXHEX:NXTMH
Nexstim — Aktiedagen Stockholm 2019
20 slides from Nexstim's conference presentation, Sep 10, 2019
Slide 1: Nexstim. Personalised depression treatment.
Nexstim. Personalised depression treatment. Mikko Karvinen| CFO | Nexstim Plc Nexstim Plc Corporate Presentation, Aktiedagen Stockholm, 10 September 2019
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: Nexstim – personalised transcranial magnetic stimulation
Nexstim – personalised transcranial magnetic stimulation Unique and Proprietary ▪ Commercial-stage med tech company with a unique, proprietary navigated neuro- Technology stimulation technology for diagnostic and therapeutic applications World Leading Centers Rely ▪ Diagnostic application well estab
Slide 4: Nexstim's TMS system differentiated by E-Field Navigation
Nexstim’s TMS system differentiated by E-Field Navigation Leading transcranial magnetic stimulation technology User Interface of Nexstim TMS system • Nexstim’s device facilitates highly accurate pre-surgical mapping • Unique e-field induced modelling • 3D MRI visualisation and stereotactic navigatio
Slide 5: Unique navigated TMS system for diagnostic and therapeutic applications
Unique navigated TMS system for diagnostic and therapeutic applications Use Application Europe US Commercial Status Diagnostic – Installed base of over Navigated Brain Pre-surgical mapping CE marked FDA approved 160 systems Stimulation (NBS) Multiple systems Therapeutic – Depression CE marked FDA ap
Slide 6: Navigated Brain Stimulation
Navigated Brain Stimulation Proprietary technology enabling substantial increase in progression- free survival in brain cancer surgery, commercially validated
Slide 7: Nexstim's NBS is the only available pre-surgical mapping technology
Nexstim’s NBS is the only available pre-surgical mapping technology World-leading Centers Rely on Nexstim‘s Pre-surgical NBS Significantly Improves Clinical Outcomes Mapping Technology NBS Selected institutions out of the 160 ones currently NBS helps surgeons to prepare better and to be more aggress
Slide 8: Navigated Brain Therapy®
Navigated Brain Therapy® Smart, focused and drug-free
Slide 9: Nexstim E-field navigation vs. line navigation
Nexstim E-field navigation vs. line navigation Line Nexstim navigated TMS coil TMS coil • Line navigation is inaccurate as it doesn’t E-field target E-field target Line navigation account for the distortion misses target caused by bone and brain matter • Nexstim’s E-field navigation accounts for tha
Slide 10: Navigated Brain Therapy® in Depression
Navigated Brain Therapy® in Depression Entering a rapidly growing market with a differentiated product
Slide 11: NBT® for Depression
NBT® for Depression Nexstim depression business opportunity Market size of estimate2 People affected by MDD globally 216m • Major depressive disorder affects 2-5% of the Patients not responding to medicines population in developed countries1 39m and seeking treatment • Existing psychotherapy and pha
Slide 12: Existing reimbursement for depression treatment and private pay represent compelling opportunity in the US
Existing reimbursement for depression treatment and private pay represent compelling opportunity in the US Economic Benefit to US TMS Centre or Psychiatric Clinic Commercialisation approach (Pay-per-use lease)1 • Most major commercial payers now reimburse TMS treatment for depression in the US and 1
Slide 13: NBT® geographic focus for depression in the US
NBT® geographic focus for depression in the US Build a direct sales field organization NORTHEAST STATES2 comprised of sales, clinical support and Population: 67 Million operations distributed across existing US Practices using TMS: 196 NBS geography and recruit sophisticated TMS Groups: 47 and well
Slide 14: Commercialization and Go-To-Market Approach – Europe & Asia
Nexstim Brain Therapy - Commercialization and Go- To Market Approach – Europe & Asia Actions on established markets • Strong distributor organization • Cross-selling NBS with NBT® • Five university hospitals in Finland using a Nexstim system for both depression and pain treatments • Patient registry
Slide 15: Navigated Brain Therapy® in Neuropathic Pain
Navigated Brain Therapy® in Neuropathic Pain
Slide 16: NBT® for Chronic Neuropathic Pain
NBT® for Chronic Neuropathic Pain Nexstim neuropathic pain business opportunity Market size of estimate2 People affected by chronic • There are about 10 million addressable neuropathic pain 285m neuropathic pain annually patients in the US and Europe1 Patients not responding to medicines and seeking
Slide 17: Key Performance Indicators
Key Performance Indicators EUR in thousands H1 2019 H1 2018 FY 2018 Net sales grew by 13%. Therapy business net sales grew 6 months 6 months 12 months strongly (170%) in H1 amounting to EUR 610.0 thousand (2018 H1: EUR 226.3 thousand) Net sales 1,217.4 1,079.3 2,672.1 The increase in personnel expen
Slide 18: Nexstim 2019 Share Offer Warrants
Nexstim 2019 Share Offer Warrants ▪ In April 2019, Nexstim arranged a share offering, which was supported by new major anchor investors, that raised EUR 3.5 million of new capital ▪ Offer Warrants were delivered to the subscribers and the trading of the warrants began on First North Finland and Firs
Slide 19: Business summary
Business summary 1 Only TMS system to provide accurate, personalised targeting of key areas of treatment Commercially validated in pre-surgical mapping with systems installed in more than 160 2 hospitals 3 First installations for depression in multiple sites across three continents 4 Focused strateg
Slide 20: Thank you!
Nexstim Thank you!